Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

Continue Reading

Stacy Gray, M.D. Receives NIH Grant for Cancer Genomics Research

September 11, 2019 | Letisia Marquez

Stacy Gray, M.D., associate clinical professor in the Division of Clinical Cancer Genomics, is one of six physicians to receive an inaugural “Genomic Innovator Award” from the National Human Genome Institute (NHGI).

Anti-PD-L1 checkpoint inhibitors: Decoding the mystery

July 24, 2019 | City of Hope

An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.

New research presented at 60th annual ASH meeting

December 19, 2018 | City of Hope

City of Hope clinical and laboratory investigators presented leading-edge research, including new targets in CAR T cell therapy, at the 60th annual ASH meeting in San Diego.

New hormone and immunotherapy trial for breast cancer patients

October 8, 2018 | City of Hope

This phase 2 trial studies the side effects and how well pembrolizumab and enobosarm work in treating patients with androgen receptor positive triple-negative breast cancer that has spread to other places in the body.

City of Hope Awarded $3.7 million to Develop Glioblastoma Clinical Trial

June 29, 2018 | Letisia Marquez

California Institute for Regenerative Medicine has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients, which would genetically alter blood stem cells to better tolerate chemotherapy.

Researchers Use Nanoparticles to Test Treatment for Liver Disease

June 25, 2018 | Katie Neith

In an effort to improve options for those with liver cancer, a group of researchers have identified a way of potentially treating a broad range of liver diseases and perhaps even other types of cancer.

Jianjun Chen, Ph.D., Takes Aim at Acute Myeloid Leukemia

May 15, 2018 | City of Hope

Jianjun Chen, Ph.D., a new faculty member at City of Hope, dedicates much of his research program to learning more about acute myeloid leukemia (AML), one of the most common and deadly forms of blood cancer.

John Williams, Ph.D.: Building Better Antibodies

April 20, 2018 | City of Hope

City of Hope researchers use novel technology to add new functionalities to already potent proteins.